Long-acting HIV-1 treatment may remove need for daily therapy
ViiV Healthcare has received Marketing Authorisation for the first complete long-acting injectable HIV treatment in Europe.
Marketing Authorisation has been granted by the European Commission for ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) to be used with Janssen’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets).
The long-acting injectable regimen was preferred by the majority of clinical trial patients who tried the treatment over their previous daily oral therapy.
ViiV Healthcare, owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi Limited as shareholders, announced the authorisation of the new treatment in the European Union (EU), for the treatment of HIV-1 infection in combination with Janssen Pharmaceutical Companies of Johnson & Johnson’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), in the EU, for the treatment of HIV-1 infection in
Spain
Santiago-de-compostela
Galicia
Janssen-rekambys
Antonio-antela
University-hospital
Glaxosmithkline
Pfizer-inc
European-union
European-commission-for-viiv-healthcare-vocabria
Janssen-pharmaceutical-companies-of-johnson-rekambys
Viiv-healthcare
Long-Acting HIV Regimen Approved in Europe
The approval of injectable drug Vocabria sets up a treatment regimen that can be taken once a month or even every other month.
The European Union has approved a new long-acting treatment for HIV.
The E.U.’s European Medicines Agency announced approval Monday of Vocabria from Viiv Healthcare. Vocabria is a cabotegravir injection and works by blocking an essential step in HIV replication cycle. Vocabria was approved for use in Europe in combination with Rekambys injections and Edurant tablets, both of which are forms of rilpivirine and are made by Janssen Pharmaceuticals.
This marks the first time people living with HIV in Europe will be able to receive a long-acting injectable treatment that removes the need to take daily oral tablets, following the oral initiation phase, according to a Viiv press release. The injections of Vocabria and Rekambys could be delivered once a month or once every two months. The treatment is appropriate for
United-states
Spain
Santiago-de-compostela
Galicia
Deborah-waterhouse
Antonio-antela
Glaxosmithkline
Eu-european-medicines-agency
Pfizer
University-hospital
European-union
Janssen-pharmaceuticals